
    PFIZER INC., Plaintiff-Counter-Defendant-Appellant, v. MCNEIL-PPC, INC., Defendant-Counter-Claimant-Appellee.
    No. 16-1743
    United States Court of Appeals, Second Circuit.
    September 15, 2017
    
      For Plaintiff-Appellant: Lynn K. Neuner (William T. Russell, Jr., and Daniel J. Stu-jenske, on the brief), Simpson Thacher & Bartlett LLP, New York, NY.
    For Defendant-Appellee: Steven A. Za-lesin (Travis J. Tu, on the brief), Patterson Belknap Webb & Tyler LLP, New York, NY; Kathryn A. Meisel, Johnsqn & Johnson, New Brunswick, NJ.
    Present: ROBERTA. KATZMANN, Chief Judge, PETER W. HALL, Circuit Judge.
    
    
      
       Judge Robert D. Sack, originally assigned to this panel, subsequently recused himself from this case. Therefore, this case is decided by the two remaining members of the panel pursuant to Second Circuit Internal Operating Procedure E(b).
    
   SUMMARY ORDER

Pfizer Inc. appeals from the order of the United States District Court for the Southern District of New York (Carter, J.), entered on April 27, 2016, granting the motion for judgment on the pleadings under Federal Rule of Civil Procedure 12(c) filed by McNeil-PPC, Inc., and denying Pfizer’s motion for judgment on the pleadings. The parties dispute the interpretation of a consent judgment (the “Judgment”) entered in 1989 by Judge William Conner, then of the United States District Court for the Southern District of New York. We assume the parties’ familiarity with the facts and procedural history of this case, as well as the issues on appeal.

“We review a judgment under Federal Rule of Civil Procedure 12(c) de novo, accepting the complaint’s factual allegations as true and drawing all reasonable inferences in the plaintiffs favor.” Kirkendall v. Halliburton, Inc., 707 F.3d 173, 178 (2d Cir. 2013). “A district court’s interpretation of a consent decree is also subject to de novo review.” Pandora Media, Inc. v. Am. Soc’y of Composers, Authors & Publishers, 785 F.3d 73, 77 (2d Cir. 2015) (per curiam). “Consent decrees ‘reflect a contract between the parties (as well as a judicial pronouncement), and ordinary rules of contract interpretation are generally applicable.’” U.S. ex rel. Anti-Discrimination Ctr. of Metro N.Y., Inc. v. Westchester Cty., 712 F.3d 761, 767 (2d Cir. 2013) (quoting Doe v. Pataki, 481 F.3d 69, 75 (2d Cir. 2007)). “[A] written agreement that is complete, clear and unambiguous on its face must be enforced according to the plain meaning of its terms.” In re World Trade Ctr. Disaster Site Litig., 754 F.3d 114, 122 (2d Cir. 2014). But “where the contract language creates ambiguity, extrinsic evidence as to the parties’ intent may properly be considered,” and “[w]here there is such extrinsic evidence, the meaning of the ambiguous contract is a question of fact for the factfinder.” JA Apparel Corp. v. Abboud, 568 F.3d 390, 397 (2d Cir. 2009).

In the instant case, the Judgment, as relevant here, enjoins Pfizer’s predecessor “from stating in words or substance in any advertisement that ADVIL is ‘like TYLENOL’ in the respect of adverse effects on the stomach.” J. App’x at 26. The question at issue in this litigation is whether “ADVIL” in the judgment refers to the Advil product for adults on the market during the 1980s litigation, or to Advil products containing ibuprofen more generally, including Advil products for children and infants. The Court looks first to whether the term “ADVIL” in the Judgment is ambiguous, when taken together with Judge Conner’s opinion in McNeilab, Inc. v. American Home Products Corp., 675 F.Supp. 819 (S.D.N.Y. 1987), which is incorporated by reference in the Judgment. The Court agrees with the district court’s view that “[o]n its face alone, the [Judgment] is ambiguous.” Pfizer Inc. v. McNeil-PPC, Inc., 183 F.Supp.3d 491, 494 (S.D.N.Y. 2016). However, the Court disagrees that the judicial decision incorporated by reference into the Judgment resolves this ambiguity, because that decision, like the Judgment itself, can reasonably be read to apply either to all Advil products whose principal active ingredient is ibuprofen or solely to the adult Advil that gave rise to the 1980s litigation. Because the Judgment, when considered in light of the sole document it incorporates by reference, is ambiguous as to whether the Judgment applies to pediatric Advil, the parties are entitled to offer extrinsic evidence as to the parties’ intended meaning.

We have considered all of the parties’ remaining arguments and have found in them no basis for altering our decision. Accordingly, the judgment of the district court is VACATED, and the case is REMANDED to the district court for further proceedings in accordance with this order. 
      
      . Contrary to the defendant's argument, the Judgment does not also incorporate by reference a prior decision in the 1980s litigation. See Am.. Home Prods. Corp. v. Johnson & Johnson, 654 F.Supp. 568 (S.D.N.Y. 1987). However, even if the Judgment were also to incorporate this decision, the Judgment would be still be ambiguous as to whether it applies to the later-approved pediatric .Advil product at issue in the instant appeal,
     